Therapeutic vaccines in renal cell carcinoma.
Therapeutic vaccines in renal cell carcinoma.
复制标题
DOI：
10.2217/thy.11.40
复制
发表时间：
2011-07
期刊：
影响因子：
--
通讯作者：
Ernstoff MS
中科院分区：
文献类型：
--
作者：
Schwaab T;Ernstoff MS
转移性肾细胞癌（mRCC）是一种致命疾病。酪氨酸激酶抑制剂（TKI）的出现改变了疾病的进程，但大多数患者将发展为耐药疾病。mRCC中基于IL-2的免疫疗法是唯一获得美国FDA批准的具有治愈性结果的治疗。mRCC的免疫疫苗方法已经研究了几十年，结果好坏参半。最近FDA批准了前列腺癌的第一种细胞免疫疗法（Provenge®），这重振了在mRCC中寻找类似疫苗方法的努力。这篇综述介绍了成功的抗癌疫苗方法所需的概念和不同的功能。
Metastatic renal cell carcinoma (mRCC) is a lethal disease. The advent of tyrosine kinase inhibitors (TKIs) has changed the disease process, yet the majority of patients will develop treatment-resistant disease. IL-2 based immunotherapy in mRCC is the only US FDA-approved treatment with curative results. Immunotherapeutic vaccine approaches to mRCC have been under investigation for several decades with mixed results. The recent FDA-approval of the first cellular immunotherapy in prostate cancer (Provenge®) has reinvigorated the search for similar vaccines approaches in mRCC. This review introduces the concepts and different features required for a successful anticancer vaccine approach.